2024 U.K. Breast Cancer Diagnostics Market

2024 U.K. Breast Cancer Diagnostics Market--CEA, CA 15-3, CA 27.29,CA 125, Estrogen Receptor, HER2, Polypeptide-Specific Antigen, Progesterone Receptor--Country Database and Analysis--2023 Supplier Shares and Strategies, 2023-2028 Volume and Sales Segment Forecasts, Emerging Technologies, Latest Instrumentation, Growth Opportunities

This new report from is available by market segment, section, individual marker, and can be customized to specific information needs and budget.

This report is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding breast cancer diagnostic testing market, in evaluating emerging opportunities and developing effective business strategies during the next five years.

The report provides granular market segmentation analysis and forecasts for major breast cancer markers; profiles leading suppliers and recent market entrants with innovative technologies and products; reviews current assays and instrumentation; evaluates emerging technologies; and offers specific opportunities and growth strategies for suppliers.

Rationale

The breast cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide breast cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

Country Analyses

Business Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially significant market appeal during the next five years.

- Design criteria for new products.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

Supplier Shares, Sales and Volume Forecasts

- Sales and market shares of major suppliers
- Five-year test volume and sales forecasts by assays

Instrumentation Review

- Analysis of major analyzers used for breast cancer testing

Technology Assessment

- Assessment of latest technologies and their potential applications for breast cancer diagnostic testing
- Review of competing/complementing technologies

- Companies, universities and research centers developing new breast cancer diagnostic tests and detection technologies

Competitive Strategies

- Strategic assessments of major suppliers and start-up firms developing innovative breast cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

- The companies analyzed in the report include:

Abbott, Affymetrix, Beckman Coulter/Danaher, Becton Dickinson, bioMerieux, Bio-Rad, DiaSorin, Eiken Chemical, Elitech Group, Enzo Biochem, Fujirebio, Fujifilm Wako, Grifols, Hologic, Leica Biosystems, PerkinElmer, Qiagen, QuidelOrtho, Roche, Siemens Healthineers, Takara Bio, Thermo Fisher, and others.

I. Introduction
II. Worldwide Market Overview
III. Major Product Development Opportunities
A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products
IV. Design Criteria for Decentralized Testing Products
V. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
VI. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VII. Worldwide Market and Technology Overview
A. Breast Cancer Statistics and Etiology
B. Breast Cancer Diagnostic Tests
1. CEA
2. CA 15-3
3. CA 27.29
4. CA 125
5. Estrogen Receptor
6. HER2
7. Polypeptide-Specific Antigen
8. Progesterone Receptor

C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
D. Current and Emerging Cancer Diagnostic Technologies
1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
3. Molecular Diagnostics
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies
E. Personal Testing
VIII. Country Market Analysis: Breast Cancer Diagnostics Market Test Volume and Sales Forecasts

IX. Competitive Profiles
The report provides strategic assessments of over 30 cancer diagnostics market players and
start-up companies with innovative technologies and products, including:
- Abbott
- Affymetrix
- Becton Dickinson
- bioMerieux
- Bio-Rad
- Danaher/Beckman Coulter/Cepheid
- DiaSorin
- Eiken Chemical
- Elitech Group
- Enzo Biochem
- Fujifilm Wako
- Fujirebio
- Grifols
- Hologic
- Leica Biosystems
- Qiagen
- QuidelOrtho
- Roche
- Siemens Healthineers
- Takara Bio
- Thermo Fisher

List Of Tables

Major Companies Developing or
Marketing CA 15-3 Tests
Major Companies Developing or
Marketing CA 27.29 Tests
Major Companies Developing or
Marketing CA 125 Tests
Major Companies Developing or
Marketing CEA Tests
Major Companies Developing or
Marketing Estrogen Receptor Tests
Major Companies Developing or
Marketing HER2 Tests
Major Companies Developing or
Marketing Polypeptide-Specific Antigen Tests
Major Companies Developing or
Marketing Progesterone Receptor Tests
U.K. Laboratories Performing Breast Cancer
Tests by Market Segment
U.K. Hospital Laboratories Performing
Breast Cancer Tests by Bed Size
U.K. Commercial/Private Laboratories
Performing Breast Cancer by Annual Test Volume
U.K. Total Breast Cancer Test Volume
Forecast by Market Segment
U.K. All Market Segments Breast
Cancer Test Volume Forecast
U.K. Hospital Laboratories Breast
Cancer Test Volume Forecast by Assay
U.K. Commercial/Private Laboratories Breast
Cancer Test Volume Forecast by Assay
U.K. Total Breast Cancer Sales by Market
Segment
U.K. All Market Segments Breast
Cancer Diagnostics Market Forecast by Test
U.K. Hospital Laboratories Breast
Cancer Diagnostics Market Forecast by Test
U.K. Commercial/Private Laboratories Breast
Cancer Diagnostics Market Forecast by Test
U.K. CEA Test Volume and Diagnostics Sales
Forecast by Market Segment
U.K. CA 15-3 Test Volume and
Diagnostics Sales Forecast by Market Segment
U.K. CA 27.29 Test Volume and
Diagnostics Sales Forecast by Market Segment
U.K. CA-125 Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K. Estrogen Receptor Test Volume and
Diagnostics Sales Forecast by Market Segment
U.K. HER2 Test Volume and Diagnostics Sales
Forecast by Market Segment
U.K. Polypeptide-Specific Antigen Test Volume and
Diagnostics Sales Forecast by Market Segment
U.K. Progesterone Receptor Test Volume and
Diagnostics Sales Forecast by Market Segment
U.K. Breast Cancer Market by Major Supplier
U.K. CEA Testing Market by Major Supplier

Fill The Form For Sample Request

There is no Reviews available